Investors previously responded coolly to CagriSema after initial overall phase 3 trial results showed a 22.7% weight loss, falling below Novo Nordisk's targeted 25% expectation

Weight management

Supports users in reaching and maintaining a healthy body weight through behavioral and nutritional tools.

413 claims·67 news stories